Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
20 Gennaio 2022 - 10:40PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing patented Microcyn® technology-based
stabilized hypochlorous acid (HOCl) products for a wide range of
applications, including wound, eye, oral and nasal care,
disinfectant use and dermatological conditions, today announced
that it has added Salus Medical as an additional distribution
partner in the United States for dental care and expanded its oral
and dental care lines to China via a partnership deal with Anlicare
International.
Sonoma entered into a non-exclusive agreement with Salus Medical
to distribute Endocyn® root canal irrigant through their existing
dental channels. In addition, Salus Medical will expand on their
cutting-edge dermatology offerings with Sonoma’s Microcyn® RX and
Regenacyn® Plus products and have non-exclusive distribution rights
for Microcyn® wound care products.
“We believe Endocyn root canal irrigant will be a great addition
to our product portfolio at Salus Medical. Both Endocyn and the
Microcyn line of products fit with our strategy of being dedicated
to delivering value to the U.S. healthcare system while combining
quality and economy,” said Hernan Alvarez, President of Salus
Medical.
Additionally, on January 18, 2022, Sonoma and Anlicare agreed to
cooperate to complete the regulatory work necessary to obtain
licenses in China to distribute Sonoma’s Microcyn® technology-based
dental and oral products. Anlicare will bear the regulatory costs
and in return, Sonoma agreed to grant Anlicare exclusive rights for
selling and distributing oral and dental care products in
China.
“We see the strength of Sonoma’s Microcyn technology in the
prevention of infection and reduction of bacteria and
microorganisms and believe Sonoma’s Microcyn technology will be
beneficial for dentistry and general oral care for both
professional and consumer use,” commented Sherwin Hu, CEO at
Anlicare International.
“We are pleased to add Salus Medical and Anlicare to our growing
network of distributors for our oral and dental products, and we
continue to seek distribution partners for our proprietary Microcyn
technology that is truly superior in terms of antimicrobial impact,
shelf stability and safety,” said Bruce Thornton, COO of Sonoma
Pharmaceuticals.
About Salus Medical
Since 2012, Salus Medical is a national wholesale distributor
based in Phoenix, Arizona. As generic wholesaler or generic
pharmaceutical distributor, Salus Medical has been focused on
delivering economy and value to its clients. Due to its focus on
client’s needs, Salus Medical has experienced tremendous growth
within its short history. As Salus Medical has developed over the
years, it has formed strategic relationships with a wide variety of
suppliers nationwide, enabling Salus Medical to supply a range of
low-cost yet high-quality products. By offering a broad portfolio
of products, Salus Medical is able to service multiple medical
facilities and providers within the healthcare continuum including
pharmacies, clinics, surgery centers, and hospitals.
About Anlicare International
Founded in 2012, the founders and management team of Anlicare
International come from top Chinese pharmaceutical companies with
decades of valuable experience of the Chinese pharmaceutical and
medical device markets. Anlicare has been working closely with
leading international medical companies and top medical clinical
teams in China in various medical fields to bring and commercialize
innovative medical devices and consumables into the Chinese
market.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care, disinfectant
use and dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company’s principal
office is in Woodstock, Georgia, with manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “develop” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development, as well as uncertainties relative to the COVID-19
pandemic and economic development, varying product formulations and
a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn®, Endocyn® and Regenacyn® are
trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc.
All other trademarks and service marks are the property of their
respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120006023/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Grafico Azioni Sonoma Pharmaceuticals (NASDAQ:SNOA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sonoma Pharmaceuticals (NASDAQ:SNOA)
Storico
Da Giu 2023 a Giu 2024